Franco Sandra, Tural Cristina, Clotet Bonaventura, Martínez Miguel Angel
Fundació irsiCaixa, Universitat Autònoma de Barcelona, Spain.
Virus Res. 2007 Feb;123(2):161-9. doi: 10.1016/j.virusres.2006.09.001. Epub 2006 Oct 4.
The hepatitis C virus (HCV) genotype 4 is spreading among southern European intravenous drug users, who are frequently co-infected with human immunodeficiency virus type 1 (HIV-1). Response to interferon (IFN) alpha-based therapies in HIV-1 positive patients co-infected with HCV genotype 4 is poor, similar to that obtained for HCV genotype 1 and much lower than for HCV genotypes 2 and 3. The lack of sequence data related to HCV of genotype 4 prompted us to sequence the complete genome of two genotype 4 variants isolated from two HIV-1 co-infected patients (24 and 25). Our aim was to investigate the evolutionary relationships of the former variants with other genotypes and/or genotype 4 subtypes. Sequence alignments and phylogenetic analysis from genomic regions 5'NC, core-E1 and NS5B revealed that the variants isolated from patients 24 and 25 (both subtyped 4c/4d by INNO-LIPA II HCV) belong to subtypes 4d and 4a, respectively. When looking at the complete genome sequence one of the variants showed a new genotype 4 subtype. Interestingly, sequence length differences in the interferon sensitivity determining region coding regions were observed when compared with sequences from other genotypes. Similarly, when the catalytic efficiency of the NS3/4 protease from patients 24 and 25 samples were determined, they displayed 70.6+/-7.7 and 23.5+/-3.4%, respectively, of the activity shown by genotype 1 NS3/4 proteases. Overall, pairwise comparison and phylogenetic analysis of nucleotide sequences of the complete genome or the different protein-encoding regions showed that genotype 4 sequences were more closely related to genotype 1 sequences. The description of new HCV genome variants may help our understanding of the HCV biology as well as the role of different genotypes in HCV treatment and therapy response.
丙型肝炎病毒(HCV)基因4型正在南欧的静脉注射吸毒者中传播,这些人经常同时感染1型人类免疫缺陷病毒(HIV-1)。与HCV基因4型合并感染的HIV-1阳性患者对基于干扰素(IFN)α的治疗反应较差,类似于HCV基因1型患者的治疗反应,且远低于HCV基因2型和3型患者。由于缺乏与HCV基因4型相关的序列数据,我们对从两名合并感染HIV-1的患者(患者24和患者25)中分离出的两个基因4型变体的完整基因组进行了测序。我们的目的是研究这些变体与其他基因型和/或基因4型亚型之间的进化关系。对5'NC、核心-E1和NS5B基因组区域的序列比对和系统发育分析表明,从患者24和患者25分离出的变体(通过INNO-LIPA II HCV检测均为4c/4d亚型)分别属于4d和4a亚型。在查看完整基因组序列时,其中一个变体显示为一种新的基因4型亚型。有趣的是,与其他基因型的序列相比,在干扰素敏感性决定区编码区域观察到了序列长度差异。同样,当测定患者24和患者25样本中NS3/4蛋白酶的催化效率时,它们分别显示出基因1型NS3/4蛋白酶活性的70.6±7.7%和23.5±3.4%。总体而言,对完整基因组或不同蛋白质编码区域的核苷酸序列进行成对比较和系统发育分析表明,基因4型序列与基因1型序列的关系更为密切。新的HCV基因组变体的描述可能有助于我们理解HCV生物学以及不同基因型在HCV治疗和治疗反应中的作用。